Free Trial

Harrow Q2 2023 Earnings Report

Harrow logo
$26.22 +1.25 (+4.98%)
As of 12:15 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Harrow EPS Results

Actual EPS
-$0.02
Consensus EPS
-$0.01
Beat/Miss
Missed by -$0.01
One Year Ago EPS
$0.01

Harrow Revenue Results

Actual Revenue
$33.47 million
Expected Revenue
$31.04 million
Beat/Miss
Beat by +$2.43 million
YoY Revenue Growth
+43.50%

Harrow Announcement Details

Quarter
Q2 2023
Time
After Market Closes

Conference Call Resources

Remove Ads

Harrow Earnings Headlines

2HROW : Where Harrow Stands With Analysts
Harrow (NASDAQ:HROW) Earns "Buy" Rating from HC Wainwright
DOGE could send 6 AI stocks through the roof
Stay alert for Elon Musk and the Department of Government Efficiency's next move … Expect an announcement from Elon any day now … Thousands of government jobs could be replaced … By a new form of AI. Recently perfected by Musk and his team at xAI.
Harrow (NASDAQ:HROW) Shares Gap Up Following Strong Earnings
See More Harrow Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Harrow? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Harrow and other key companies, straight to your email.

About Harrow

Harrow (NASDAQ:HROW) operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in Nashville, Tennessee.

View Harrow Profile

More Earnings Resources from MarketBeat